Population Pharmacokinetics, Effectiveness and Safety of Cefuroxime in Neonates
NCT ID: NCT05388747
Last Updated: 2022-05-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
100 participants
OBSERVATIONAL
2022-05-16
2025-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Pharmacokinetics and Safety of Ceftobiprole in Neonates and Infants up to 3 Months Treated With Systemic Antibiotics
NCT02527681
A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Cefiderocol in Hospitalized Neonates and Infants
NCT06086626
Selective Use of Antibiotics in Neonates Born to Mothers With Suspected Chorioamnionitis
NCT03576560
Pilot Study - Monitoring the Nasal Microbiome and Viral Respiratory Infections in Newborn Hospitalized in Neonatalogy.
NCT06389383
Symptom Spectrum and Risk Factors for Fever in Pediatric and Adult Patients With Omicron Infection
NCT06463821
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Cefuroxime
Population pharmacokinetics, effectiveness, and safety of cefuroxime
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Cefuroxime used as part of antimicrobial treatment;
* Parental written consent.
Exclusion Criteria
* Receiving other systemic trial drug therapy;
* Other factors that the researcher considers unsuitable for inclusion.
0 Days
28 Days
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Tianjin Central Hospital of Gynecology Obstetrics
OTHER
Shandong University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Wei Zhao
Head of department of clinical pharmacy and pharmacology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tianjin Central Hospital of Gynecology Obstetrics
Tianjin, Tianjin Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2022-PPK-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.